SynthesisFrontiers in oncology2025
Prognostic and clinicopathological role of soluble programmed cell death ligand-1 in patients with diffuse large B-cell lymphoma: a meta-analysis.
Synthesis in Frontiers in oncology, 2025. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 2 papers, 1 of them a synthesis that pooled it.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
2 citing papers in PubMed, 1 synthesis or guideline pooled it.
- Prognostic and clinicopathological value of soluble programmed cell death ligand-1 (sPD-L1) in patients with colorectal cancer: a meta-analysis.World journal of surgical oncology · 2025Pooled it
- [Characteristics and survival analysis of 60 cases of primary diffuse large B-cell lymphoma of the breast].Zhonghua xue ye xue za zhi = Zhonghua xueyexue zazhi · 2026Article
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
7 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
Background: The significance of soluble programmed death protein ligand-1 (PD-L1) in predicting the prognosis of diffuse large B-cell lymphoma (DLBCL) has been previously analyzed, but with conflicting results. This study investigated the effect of soluble PD-L1 (sPD-L1) expression on the prognosis of patients with DLBCL. Methods: We comprehensively searched the Web of Science, PubMed, Embase, and CNKI databases between their inception and August 14, 2024. The value of sPD-L1 in predicting the overall survival (OS) and progression-free survival (PFS) of patients with DLBCL was analyzed by computing the combined hazard ratios (HRs) and 95% confidence intervals (CIs). Associations between sPD-L1 and the clinicopathological factors of DLBCL were explored by combining odds ratios (ORs) and 95%CIs. Results: Seven articles involving 826 patients were included in this meta-analysis. Based on our pooled data, elevated sPD-L1 was closely related to poor OS (HR = 2.81, 95%CI = 1.99-3.95, p < 0.001) and inferior PFS (HR = 3.16, 95%CI = 1.41-7.08, p = 0.005) of DLBCL. Moreover, based on the pooled data, higher sPD-L1 was significantly related to the Eastern Cooperative Oncology Group Performance Status Scale (ECOG PS) ≥2 (OR=4.10, 95%CI=1.82-9.24, p=0.001), clinical stage III-IV (OR = 3.30, 95%CI = 1.48-7.39, p = 0.004), elevated lactate dehydrogenase (LDH) levels (OR = 2.14, 95%CI = 1.07-4.30, p = 0.032), and the International Prognostic Index (IPI) score 3-5 (OR = 3.83, 95%CI = 1.91-7.68, p < 0.001) in DLBCL. Conclusion: According to our findings, a higher sPD-L1 level was a significant predictor of poor OS and PFS in patients with DLBCL. Elevated sPD-L1 levels are closely related to factors representing disease aggressiveness in DLBCL.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.